Meta-analysis of Shenqi Fuzheng Injection Assisting TACE in the Adjuvant Treatment of Primary Liver Carcinoma
10.6039/j.issn.1001-0408.2017.27.16
- VernacularTitle:参芪扶正注射液辅助TACE治疗原发性肝癌的Meta分析
- Author:
Hui CAO
1
;
Zhong XU
;
Lingling ZHANG
;
Banjun BAI
Author Information
1. 贵州省人民医院,贵阳550002
- Keywords:
Shenqi fuzheng injection;
Primary liver carcinoma;
TACE;
Randomized controlled trial;
Meta-analysis;
Therapeutic efficacy;
safety
- From:
China Pharmacy
2017;28(27):3804-3808
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the effectiveness and safety of Shenqi fuzheng injection assisting TACE in the adjuvant treatment of primary liver carcinoma,and to provide evidence-based reference.METHODS:Retrieved from CJFD,Wanfang database,VIP and PubMed,randomized controlled trials (RCTs) about Shenqi fuzheng injection assisting TACE (trial group) vs.TACE alone (control group) in the treatment of primary liver carcinoma were collected.Meta-analysis was performed by using Stata 12.0 software after data extraction and quality evaluation according to improved Jadad scale.RESULTS:A total of 8 RCTs were included,involving 527 patients.Results of Meta-analysis showed that there was no statistical significance in response rate [RR=1.19,95％CI(0.97,1.46),P=0.091] and clinical benefit rate [RR=1.16,95％CI(0.90,1.48),P=0.251] of 2 groups.The rate of life quality improvement in trial group was significantly higher than control group [RR=2.26,95 ％ CI (1.64,3.10),P=0.001],while the incidence of above middle fever [RR=0.74,95％ CI (0.63,0.88),P=0.001],gastrointestinal reaction [RR=0.52,95％ CI (0.32,0.85),P=0.010] and leucocyte reduction rate [RR=0.75,95％ CI (0.62,0.92),P=0.005],were significantly lower than control group,with statistical significance.CONCLUSIONS:Shenqi fuzheng injection assisting TACE for primary liver carcinoma cannot improve therapeutic efficacy but improve the quality of life and reduce the incidence of gastrointestinal reaction and leucocyte reduction.
